- NewGenIvf posted net income of US$ 9.7 million for fiscal 2025, versus a net loss a year earlier, helped by a US$ 22 million bargain purchase gain.
- Revenue fell 13.01% to US$ 4.7 million, as IVF treatment services dropped 28.11% to US$ 3.9 million on a management change at Thailand clinic and a new Kyrgyzstan clinic set-up in late 2024.
- Operating loss widened to US$ 11 million as operating expenses more than tripled to US$ 12 million, driven by higher professional fees and personnel costs.
- Fertility referral services contributed US$ 1 million of revenue following launch in 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NewGenIvf Group Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-037687), on March 31, 2026, and is solely responsible for the information contained therein.
Comments